Atamyo Pharma Secures Approval from European Regulators to Commence Human Trials of ATA-200, Their Innovative Genetic Treatment for Limb-Girdle Muscular Dystrophy 2C/R5.

CinFina Pharma Reveals US Health Authority's Approval for Early-Stage Drug Trial and Commencement of Dosing in Initial Human Subjects for its Obesity Medication, CIN-110.

Astellas Pharma Inc. announced that Japan's Ministry of Health, Labour and Welfare approved VYLOY™ (zolbetuximab), an anti-CLDN18.2 drug, for advanced and inoperable metastatic stomach cancer patients positive for CLDN18.2.

Initial enrollment of patients with stomach and esophageal cancer has begun for a second-stage mixed studies trial, utilizing Affibody's ABY-025 diagnostic tool for positron emission tomography.

Corteria Pharmaceuticals has launched the first stage of clinical trials to assess the efficacy of their CRF2 activator, COR-1167, specifically targeting the progression of cardiac insufficiency.

Intravacc, a globally recognized pioneer in the field of translational research as well as the creation of vaccines for both prevention and treatment, has shared encouraging results from initial human trials of Avacc 10.

Aptamer Sciences Submits New Drug Application for Groundbreaking Hepatocellular Carcinoma Therapy AST-201: A Potential Solution for Unmet Treatment Requirements.

Novo Nordisk has entered into an acquisition agreement with Cardior Pharmaceuticals, with the deal amounting to a maximum of 1.025 billion Euros.

Apogee Therapeutics has initiated dosing of initial volunteers in a Phase 1 study of their new extended-duration IL-4Rα antibody, APG808, aimed at managing Chronic Obstructive Pulmonary Disease (COPD) and various inflammatory conditions.

Regeneron Pharmaceuticals, Inc. has declared the receipt of Complete Response Letters from the U.S. Food and Drug Administration concerning their submitted Biologics License Application for the drug odronextamab.

Rhythm Pharma Initiates First Human Dosing in Early-Stage Study of RM-718, a Once-Weekly Compound Targeting MC4R Receptors.

US FDA grants Bio-Thera Solutions approval to start Phase II trial of BAT8006, a novel ADC aimed at Folate Receptor alpha.